{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:20:03Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 14.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09557-6e85-7243-85ff-85d6810191cd\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: minaprine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 regis", "usd": 0.0, "recall": true }, "codex": { "seconds": 72.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09557-6e7e-7d51-8918-3c048508a9ac\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: minaprine\nRegistry id: vr.tr.minaprine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCont" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:50:27+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q6863173", "registryId": "vr.tr.minaprine", "name": "minaprine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q6863173/", "model": { "registry_id": "vr.tr.minaprine", "name": "minaprine", "purpose": "Enable an agent to identify minaprine, assess the form and quality of a material containing it, and determine which handling or research actions are supported by evidence.", "definition": "Minaprine is a synthetic aminopyridazine compound formerly used as an antidepressant whose clinical use was discontinued because of seizure risk.", "scope_statement": "This model owns the chemical identity of minaprine under vr.tr.minaprine in PHY / PHY.MAT, its material forms, analytical quality, experimentally qualified biological properties, and substance-specific constraints on use.", "in_scope": [ "Minaprine molecular identity and reconciliation of chemical identifiers", "Distinction between the parent compound, protonated forms, and specified salts", "Sample composition, purity, impurities, and condition-dependent physical properties", "Minaprine pharmacology and metabolism with explicit experimental context", "Substance hazards, storage requirements, and jurisdiction-specific use restrictions" ], "out_of_scope": [ "Finished medicinal products, their excipients, packaging, and commercial identity", "Patient diagnosis, prescribing, dosing, and treatment selection", "Manufacturing processes and synthesis equipment", "Independent models of metabolites, analogues, and degradation products", "General models of depression, neurotransmission, or laboratory safety" ], "distinguishing_features": [ "Match the parent molecular structure to 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine rather than accepting an antidepressant label as identification.", "Check the parent formula C17H22N4O and PubChem CID 4199 against the supplied structural identifier; formula alone cannot exclude structural isomers.", "Distinguish the parent compound from minaprine dihydrochloride by counterion content and stoichiometry before comparing mass concentrations.", "Require analytical separation from related compounds and transformation products; similar pharmacological activity does not establish chemical identity.", "Treat a historical brand name as a link to a product record, requiring confirmation of its active ingredient and salt form." ], "characteristics": [ { "name": "Parent chemical identity", "kind": "category", "unit_or_values": "C17H22N4O; CAS 25905-77-5; PubChem CID 4199; InChIKey LDMWSLGGVTVJPG-UHFFFAOYSA-N", "why_it_matters": "Provides a reference identity for reconciling labels and analytical records. Reference: [PubChem minaprine](https://pubchem.ncbi.nlm.nih.gov/compound/Minaprine)." }, { "name": "Parent molar mass", "kind": "measurement", "unit_or_values": "Approximately 298.38 g/mol for the neutral parent", "why_it_matters": "Supports molar calculations only when the actual material form is accounted for. Reference: [NIST Chemistry WebBook](https://webbook.nist.gov/cgi/inchi?ID=C25905775&Units=SI)." }, { "name": "Material form", "kind": "category", "unit_or_values": "Parent compound; specified salt with counterion ratio; hydrate or solvate if demonstrated; solution", "why_it_matters": "Determines the appropriate formula mass, concentration basis, and interpretation of physical-property data." }, { "name": "Assay and impurity profile", "kind": "measurement", "unit_or_values": "Mass fraction or amount fraction; chromatographic area percentage recorded separately; method and uncertainty", "why_it_matters": "Distinguishes actual minaprine content from a supplier purity claim or an uncorrected chromatographic result." }, { "name": "Physical behavior", "kind": "measurement", "unit_or_values": "Solubility in mg/mL or mol/L with solvent, pH, and temperature; thermal transitions in °C with method and material form", "why_it_matters": "Supports preparation and storage decisions without transferring values between the parent compound and salts." }, { "name": "Experimental pharmacological activity", "kind": "measurement", "unit_or_values": "Endpoint-specific potency or effect with units, assay system, species, exposure duration, and tested form", "why_it_matters": "Prevents a result from one assay from becoming an unconditional statement about mechanism or human efficacy." }, { "name": "Transformation relationships", "kind": "relation", "unit_or_values": "Parent-to-metabolite or degradation-product relation with supporting identification evidence", "why_it_matters": "Separates minaprine exposure and activity from those of chemically distinct transformation products." }, { "name": "Permitted-use status", "kind": "state", "unit_or_values": "Jurisdiction, date, intended use, authority, and documented status or unknown", "why_it_matters": "Separates historical medicinal use from current authorization and laboratory availability." } ], "affordances": [ "Reconcile a supplier label, analytical result, or historical record with the minaprine parent identity.", "Convert a verified salt amount into parent-equivalent amount using stoichiometry, assay, and water or solvent content.", "Assess whether a minaprine batch is suitable for a specified analytical or research purpose.", "Compare pharmacological observations only after aligning tested form, concentration basis, and experimental conditions.", "Determine whether documented storage, handling, and use conditions cover a proposed operation.", "Flag unresolved identity, quality, or regulatory evidence before releasing material for use." ], "agent_conduct": { "may": [ "Identify minaprine by name, identifiers and documented properties, citing sources.", "Report its withdrawal and the reasons from official and historical sources.", "Check a research sample's documentation against its stated identity." ], "must_not": [ "Recommend it for depression or for any particular person.", "Help supply it outside lawful research or pharmaceutical channels.", "Present its discontinued use as current approved practice.", "Minimize the seizure risk that led to its withdrawal." ], "requires_human": [ "Any use of a sample in human research.", "Destroying or transferring research stocks." ] }, "ethics": { "considerations": [ "People with depression deserve honest information about treatments that were withdrawn.", "Withdrawn medicines can reappear through unregulated sellers." ], "affected_parties": [ "People with depression", "Research participants", "Researchers" ] }, "owners": { "steward": "The research institution holding a sample; medicines regulators for its withdrawn status.", "master_systems": [] }, "visual_identification": [ "Identity rests on the label and analytical certificate, not appearance." ], "failure_modes_and_hazards": [ "Seizure risk, which led to discontinuation of clinical use.", "Unregulated material may be mislabelled or contaminated." ], "standards_and_regulation": [ "Globally Harmonized System of Classification and Labelling of Chemicals (GHS), United Nations." ], "what_it_is_for": [ "Minaprine is encountered in historical pharmaceutical records and research on compounds formerly used as antidepressants.", "Reference materials and archived samples may support chemical identification, analytical method development and investigation of its pharmacological effects." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q6863173: minaprine", "url": "https://www.wikidata.org/wiki/Q6863173", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Minaprine", "url": "https://en.wikipedia.org/wiki/Minaprine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "minaprine-identity-and-forms", "name": "Minaprine identity and forms", "description": "Establish the parent identity and its relationship to the actual material being assessed.", "rationale": "Parent-compound records and hydrochloride material records must remain distinguishable without creating competing identities for the registered thing.", "layers": [ { "id": "parent-structure", "name": "Parent structure", "description": "Anchor recognition to molecular connectivity and verified identifiers.", "findings": [ { "id": "reference-identity", "name": "Reference identity", "description": "Use the parent structure and identifiers as the recognition anchor. Reference: [PubChem minaprine](https://pubchem.ncbi.nlm.nih.gov/compound/Minaprine).", "questions": [ { "text": "Does the candidate structure match minaprine's substituted pyridazine, phenyl group, and morpholinoethylamino substituent?", "kind": "definition", "id": "reference-identity-q01" }, { "text": "Which authoritative record connects the supplied name and identifier to that structure?", "kind": "provenance", "id": "reference-identity-q02" } ] } ] }, { "id": "salt-and-product-boundaries", "name": "Salt and product boundaries", "description": "Separate the parent identity from counterions and finished formulations.", "findings": [ { "id": "actual-material-form", "name": "Actual material form", "description": "Record salt stoichiometry explicitly; the PubChem hydrochloride record describes a two-HCl composition. Reference: [PubChem minaprine hydrochloride](https://pubchem.ncbi.nlm.nih.gov/compound/33254).", "questions": [ { "text": "Is the material the parent compound or a verified salt, and what counterion ratio, water content, or solvation is present?", "kind": "measurement", "id": "actual-material-form-q01" }, { "text": "Does a supplied commercial name identify the substance form or a finished product requiring a separate linked model?", "kind": "boundary", "id": "actual-material-form-q02" } ] } ] } ] }, { "id": "minaprine-quality-and-quantification", "name": "Minaprine quality and quantification", "description": "Determine how much minaprine a sample contains and whether its identity and quality are sufficiently established.", "rationale": "Salt mass, parent-equivalent mass, and chromatographic purity are different quantities that affect interpretation of minaprine experiments.", "layers": [ { "id": "identity-and-impurities", "name": "Identity and impurities", "description": "Connect batch acceptance to analytical evidence.", "findings": [ { "id": "analytical-specificity", "name": "Analytical specificity", "description": "Require methods capable of distinguishing minaprine from related compounds and altered material.", "questions": [ { "text": "Which structural and separation measurements confirm minaprine identity independently of the container label?", "kind": "measurement", "id": "analytical-specificity-q01" }, { "text": "Which related substances, residual solvents, or degradation products were assessed, and what detection limits apply?", "kind": "measurement", "id": "analytical-specificity-q02" } ] } ] }, { "id": "content-and-concentration", "name": "Content and concentration", "description": "Make assay and concentration calculations interpretable across material forms.", "findings": [ { "id": "parent-equivalent-content", "name": "Parent-equivalent content", "description": "State whether reported quantities refer to the weighed material, its salt, or minaprine parent equivalents.", "questions": [ { "text": "Is the reported assay a calibrated content measurement or chromatographic area percentage, and on what moisture basis?", "kind": "measurement", "id": "parent-equivalent-content-q01" }, { "text": "What verified stoichiometry and assay corrections are needed to prepare the requested minaprine molar concentration?", "kind": "action", "id": "parent-equivalent-content-q02" } ] } ] } ] }, { "id": "minaprine-physical-state-and-stability", "name": "Minaprine physical state and stability", "description": "Qualify physical-property and stability evidence by material form and environment.", "rationale": "A minaprine preparation can be incorrectly assessed if salt-specific solubility or thermal data are assigned to the parent compound.", "layers": [ { "id": "phase-and-solution-behavior", "name": "Phase and solution behavior", "description": "Record properties needed to prepare and recognize the tested material.", "findings": [ { "id": "form-specific-properties", "name": "Form-specific properties", "description": "Attach phase, thermal, and dissolution observations to an identified minaprine form.", "questions": [ { "text": "Which melting, decomposition, or other thermal observations were measured for this exact minaprine form and by what method?", "kind": "measurement", "id": "form-specific-properties-q01" }, { "text": "At the proposed solvent composition, pH, temperature, and concentration, does the material dissolve completely and remain dissolved?", "kind": "measurement", "id": "form-specific-properties-q02" } ] } ] }, { "id": "storage-and-preparation-history", "name": "Storage and preparation history", "description": "Assess whether prior conditions compromise the intended use.", "findings": [ { "id": "retained-material-integrity", "name": "Retained material integrity", "description": "Base storage and prepared-solution validity on evidence for the relevant form and container conditions.", "questions": [ { "text": "What evidence supports the assigned storage conditions and retest period for this solid or minaprine solution?", "kind": "provenance", "id": "retained-material-integrity-q01" }, { "text": "Which observed excursion, precipitate, or analytical change requires reanalysis or rejection before use?", "kind": "action", "id": "retained-material-integrity-q02" } ] } ] } ] }, { "id": "minaprine-biological-evidence", "name": "Minaprine biological evidence", "description": "Represent pharmacological and metabolic observations with their experimental limits.", "rationale": "Minaprine has a complex pharmacological literature; a broad antidepressant label cannot substitute for assay-specific evidence.", "layers": [ { "id": "activity-and-mechanism", "name": "Activity and mechanism", "description": "Distinguish observed effects from proposed molecular explanations.", "findings": [ { "id": "qualified-pharmacological-claims", "name": "Qualified pharmacological claims", "description": "An experimental report describes serotonergic and dopaminergic effects while leaving their mechanisms unresolved. Reference: [Pharmacologic profile of minaprine](https://pubmed.ncbi.nlm.nih.gov/3489135/).", "questions": [ { "text": "For each claimed monoamine oxidase, uptake, receptor, or cholinergic effect, what direct assay and concentration-response evidence exists?", "kind": "provenance", "id": "qualified-pharmacological-claims-q01" }, { "text": "Does the observation demonstrate direct target activity, a downstream effect, or an organism-level behavioral response?", "kind": "boundary", "id": "qualified-pharmacological-claims-q02" } ] } ] }, { "id": "exposure-and-transformation", "name": "Exposure and transformation", "description": "Separate administered material from measured parent and transformation-product exposure.", "findings": [ { "id": "parent-versus-product-exposure", "name": "Parent versus product exposure", "description": "Keep metabolite identity, formation, and activity claims distinct from evidence about minaprine itself.", "questions": [ { "text": "Which metabolites are analytically confirmed in the studied species or biological preparation, and which enzyme assignments have direct evidence?", "kind": "provenance", "id": "parent-versus-product-exposure-q01" }, { "text": "Were the reported exposure and effects measured for minaprine itself, an identified metabolite, or unresolved total drug-related material?", "kind": "boundary", "id": "parent-versus-product-exposure-q02" } ] } ] } ] }, { "id": "minaprine-hazards-and-use-status", "name": "Minaprine hazards and use status", "description": "Connect material handling and proposed use to documented hazard and authorization evidence.", "rationale": "Historical medicinal use, present research availability, and permission for a particular use require separate evidence.", "layers": [ { "id": "hazard-evidence", "name": "Hazard evidence", "description": "Identify applicable material hazards and unresolved toxicological signals.", "findings": [ { "id": "form-specific-safety-assessment", "name": "Form-specific safety assessment", "description": "Evaluate the actual minaprine form and operation using traceable hazard records rather than inferring safety from historical use.", "questions": [ { "text": "Which current safety data sheet and jurisdictional classification apply to this minaprine form, and are any exposure limits established?", "kind": "provenance", "id": "form-specific-safety-assessment-q01" }, { "text": "What primary evidence establishes any convulsion-related hazard, and under which exposure conditions was it observed?", "kind": "provenance", "id": "form-specific-safety-assessment-q02" }, { "text": "What containment and disposal requirements follow for the proposed weighing, dissolution, or analytical operation?", "kind": "action", "id": "form-specific-safety-assessment-q03" } ] } ] }, { "id": "historical-and-current-status", "name": "Historical and current status", "description": "Track medicinal history and present restrictions by territory and intended use.", "findings": [ { "id": "authorized-use-boundary", "name": "Authorized-use boundary", "description": "Require dated authority records before treating minaprine as authorized, withdrawn, restricted, or available for a particular purpose.", "questions": [ { "text": "Which regulator records establish minaprine's historical authorization or withdrawal, including territory, date, and stated reason?", "kind": "provenance", "id": "authorized-use-boundary-q01" }, { "text": "What current rules govern acquiring, importing, possessing, or using this material for the proposed purpose in the relevant jurisdiction?", "kind": "action", "id": "authorized-use-boundary-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This description is based on recall, without source consultation.", "Verify CAS and database identifiers, molecular properties, and the distinction between the parent compound and marketed salt forms.", "Check authoritative records for country-specific withdrawal dates and current regulatory status; detailed mechanisms of action also require verification." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of minaprine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "minaprine", "note": "Names the active drug substance rather than a particular medicinal product." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of minaprine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Historical treatment of depressive disorders.", "Experimental investigation of antidepressant and central nervous system pharmacology." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of minaprine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Can provoke seizures; this adverse effect was associated with its withdrawal from clinical use." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of minaprine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Aminopyridazines", "difference": "Aminopyridazines are a broader chemical class; minaprine is one specific substituted member." }, { "name": "Minaprine-containing medicinal products", "difference": "A medicinal product has a formulation, dose and excipients; minaprine denotes the active chemical substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of minaprine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative records resolve inconsistent parent-versus-hydrochloride naming and identifier assignments in supplier catalogues?", "What experimentally supported solubility, thermal-transition, ionization, and stability values exist for each relevant minaprine form?", "Which proposed pharmacological mechanisms are directly demonstrated at relevant exposures, and how much activity is attributable to metabolites?", "Which primary regulatory documents establish the reported convulsion-related withdrawal history and current status in each relevant territory?", "Which applicable hazard classifications, exposure limits, and validated impurity acceptance criteria exist for minaprine research materials?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 15, "questions": 26 } }